Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half

While Ginkgo Bioworks Holdings Inc’s (NYSE:DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.

The Ginkgo Bioworks Analyst: Derik de Bruin downgraded the rating for Ginkgo Bioworks from Neutral to Underperform, while reducing the price target from $6 to $3.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.